Incyte (INCY) said Monday that results from a phase 1/2 trial of latarcibart showed an 81% median reduction in annualized bleeding rate in patients with von Willebrand disease, a type of bleeding disorder.
The treatment was also found to be safe and well tolerated.
A phase 3 trial for the drug is currently enrolling, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.